Can Mavyret (glecaprevir/pibrentasvir) be taken twice daily (bid) instead of three times daily (tid)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Mavyret Must Be Taken Once Daily, Not BID or TID

Mavyret (glecaprevir/pibrentasvir) is dosed as 3 tablets taken together once daily with food—it cannot be split into twice-daily (BID) or three-times-daily (TID) dosing. This is the FDA-approved and guideline-recommended regimen that has been studied and proven effective 1.

Why Once-Daily Dosing Is Required

The pharmacokinetic profile of Mavyret was specifically designed and tested for once-daily administration:

  • Glecaprevir has a half-life of approximately 6 hours 2
  • Pibrentasvir has a half-life of approximately 23 hours 2
  • The combination achieves therapeutic drug levels when all 3 tablets (300 mg glecaprevir/120 mg pibrentasvir total daily dose) are taken together once daily 1

Food significantly increases glecaprevir absorption by 83-163%, which is why the medication must be taken with food 2. Splitting the dose would alter these carefully calibrated pharmacokinetics and potentially compromise efficacy.

Clinical Trial Evidence

All pivotal trials that established Mavyret's high cure rates (96-100% SVR12) used once-daily dosing 3, 4, 5:

  • The EXPEDITION-1 trial achieved 99% SVR12 in cirrhotic patients with once-daily dosing 3
  • The ENDURANCE trials demonstrated 95-99% cure rates across genotypes 1-6 with once-daily administration 4
  • The EXPEDITION-8 trial showed 97.7% SVR12 in treatment-naïve patients with compensated cirrhosis using once-daily dosing 5

No studies have evaluated or validated BID or TID dosing schedules for Mavyret.

Guideline Recommendations

The 2020 EASL guidelines explicitly state: "The recommended dose is 3 tablets taken orally once daily with food" 2. The 2020 AASLD-IDSA guidelines similarly recommend once-daily dosing for all approved indications 6.

Critical Pitfalls to Avoid

  • Do not split the daily dose: There is no evidence supporting divided dosing, and doing so may lead to subtherapeutic drug levels and treatment failure
  • Do not confuse with other HCV regimens: Some older interferon-based regimens required multiple daily doses, but modern DAAs like Mavyret are designed for once-daily convenience
  • Ensure adherence to food requirement: Taking without food reduces glecaprevir exposure by up to 62%, potentially compromising efficacy 2

Practical Administration

For patients who have difficulty swallowing three tablets at once:

  • The tablets can be taken sequentially within the same dosing occasion, but all three must be taken together (not split throughout the day) 1
  • For pediatric patients <45 kg, oral pellet formulations are available that are also dosed once daily 1

The once-daily regimen maximizes both efficacy and adherence—there is no clinical rationale or evidence base for altering this to BID or TID dosing.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.